The Journal of Pediatrics
Volume 150, Issue 3 , Pages 235-240.e1 , March 2007

Early Inhaled Nitric Oxide Therapy for Term and Near-Term Newborn Infants with Hypoxic Respiratory Failure: Neurodevelopmental Follow-Up

Received 5 April 2006 ,Revised 5 October 2006 ,Accepted 30 November 2006.

References 

  1. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336:597–604
  2. Roberts JD, Fineman JR, Morin FC, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med. 1997;336:605–610
  3. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Clinical Inhaled Nitric Oxide Research Group Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342:469–474
  4. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double masked, placebo controlled, dose-response, multicenter study. Pediatrics. 1998;101:325–334
  5. American Academy of Pediatrics Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics. 2000;106:344–345
  6. Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, et al. Neonatal Inhaled Nitric Oxide Study Group A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics. 2004;113:559–564
  7. Bayley N. Bayley Scales of Infant Development II. San Antonio, TX: Psychological Corp; 1993;
  8. Amiel-Tison C. Neuromotor status. In:  Taeush HW,  Yogman MW editor. Follow-up management of the high risk infant. Boston: Little, Brown; 1987;p. 115–126
  9. Northern J, Downs M. Hearing in children. Baltimore: Williams & Wilkins; 1978;
  10. Barker LE, Luman ET, McCauley MM, Chu SY. Assessing equivalence: an alternative to the use of difference tests for measuring disparities in vaccination coverage. Am J Epidemiol. 2002;156:1056–1061
  11. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the Neonatal Inhaled Nitric Oxide Study Group (NINOS). J Pediatr. 2000;136:611–617
  12. Cheung PY, Tyebkhan JM, Peliowski A, Ainsworth W, Robertson CM. Prolonged use of pancuronium bromide and sensorineural hearing loss in childhood survivors of congenital diaphragmatic hernia. J Pediatr. 1999;135:233–239
  13. Cheung PY, Haluschak MM, Finer NN, Robertson CM. Sensorineural hearing loss in survivors of neonatal extracorporeal membrane oxygenation. Early Hum Dev. 1996;44:225–233
  14. Marron MJ, Crisafi MA, Driscoll JM, Wung JT, Driscoll YT, Fay TH, et al. Hearing and neurodevelopmental outcome in survivors of persistent pulmonary hypertension of the newborn. Pediatrics. 1992;90:392–396
  15. Hendricks-Munoz KD, Walton JP. Hearing loss in infants with persistent fetal circulation. Pediatrics. 1988;81:650–656
  16. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350:1304–1313
  17. Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental outcomes of extremely low birth weight infants <32 weeks’ gestation between 1993 and 1998. Pediatrics. 2005;116:635–643
  18. Rosenberg AA, Kennaugh JM, Moreland SG, Fashaw LM, Hale KA, Torielli FM, et al. Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension. J Pediatr. 1997;131(Pt 1):70–75
  19. Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT. Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. J Pediatr. 2002;140:306–310

 All other affiliations can be found within the Appendix (available at www.jpeds.com).Supported by the National Institute of Child and Health and Human Development Neonatal Research Network (grants U10 HD21397, U10 HD40689, U10 HD21385, U10 HD21415, U10 HD21397, U10 HD27881, M01 RR00997, U10 HD27853, M01 RR08084, U10 HD27856, M01RR00750, U10 HD27871, M01RR06022, U10 HD27904, U10 HD27880, M01 RR00070, U10 HD34216, U10 HD34167, M01 RR02635, M01 RR02172, M01RR01032, and U10 HD21373) and the Canadian Institute of Health Research (grant UI 15246). Study gas and delivery devices were provided by INO Therapeutics Inc, Clinton, NJ.

PII: S0022-3476(06)01175-9

doi: 10.1016/j.jpeds.2006.11.065

The Journal of Pediatrics
Volume 150, Issue 3 , Pages 235-240.e1 , March 2007

Article Tools